N Penel

Summary

Affiliation: Centre Oscar Lambret
Country: France

Publications

  1. ncbi request reprint Additional direct medical costs associated with nosocomial infections after head and neck cancer surgery: a hospital-perspective analysis
    N Penel
    Département de Cancérologie Générale, Centre Oscar Lambret, Lille, France
    Int J Oral Maxillofac Surg 37:135-9. 2008
  2. pmc Megestrol acetate versus metronomic cyclophosphamide in patients having exhausted all effective therapies under standard care
    N Penel
    Centre Oscar Lambret, Lille, France
    Br J Cancer 102:1207-12. 2010
  3. pmc Prediction of early death among patients enrolled in phase I trials: development and validation of a new model based on platelet count and albumin
    A Ploquin
    Centre Oscar Lambret, Medical Oncology Department, 3 rue Combemale, Lille 59020, France
    Br J Cancer 107:1025-30. 2012
  4. pmc Predictive value of clinical judgment of tumour progression in phase II trials
    Nuria Kotecki
    Centre Oscar Lambret, Lille, France
    PLoS ONE 7:e52638. 2012
  5. pmc Frequency of certain established risk factors in soft tissue sarcomas in adults: a prospective descriptive study of 658 cases
    Nicolas Penel
    Département de Cancérologie Générale, Centre Oscar Lambret, 59020 Lille, France
    Sarcoma 2008:459386. 2008
  6. pmc Solitary fibrous tumors and so-called hemangiopericytoma
    Nicolas Penel
    General Oncology Department, Centre Oscar Lambret, 3 Rue F Combemale, 59020 Lille, France
    Sarcoma 2012:690251. 2012
  7. ncbi request reprint Activity endpoints reported in soft tissue sarcoma phase II trials: quality of reported endpoints and correlation with overall survival
    Nicolas Penel
    General Oncology Department, Centre Oscar Lambret, Lille, France Unit Research EA 2694, Medical School, Lille Nord de France University, Lille, France Electronic address
    Crit Rev Oncol Hematol 88:309-17. 2013
  8. pmc Long-term outcome and effect of maintenance therapy in patients with advanced sarcoma treated with trabectedin: an analysis of 181 patients of the French ATU compassionate use program
    Jean Yves Blay
    Centre Leon Berard, Lyon, France
    BMC Cancer 13:64. 2013
  9. doi request reprint Growth modulation index as metric of clinical benefit assessment among advanced soft tissue sarcoma patients receiving trabectedin as a salvage therapy
    N Penel
    Medical Oncology Department, Centre Oscar Lambret, Lille, France
    Ann Oncol 24:537-42. 2013
  10. pmc What does a modified-Fibonacci dose-escalation actually correspond to?
    Nicolas Penel
    Methodology and Biostatistics Unit, Centre Oscar Lambret, 3 Rue Frederic Combemale, 59020, Lille Cedex, France
    BMC Med Res Methodol 12:103. 2012

Detail Information

Publications97

  1. ncbi request reprint Additional direct medical costs associated with nosocomial infections after head and neck cancer surgery: a hospital-perspective analysis
    N Penel
    Département de Cancérologie Générale, Centre Oscar Lambret, Lille, France
    Int J Oral Maxillofac Surg 37:135-9. 2008
    ..These results support the application of preventive interventions to reduce nosocomial infections in this setting...
  2. pmc Megestrol acetate versus metronomic cyclophosphamide in patients having exhausted all effective therapies under standard care
    N Penel
    Centre Oscar Lambret, Lille, France
    Br J Cancer 102:1207-12. 2010
    ..To evaluate the antitumour activity and safety of metronomic cyclophosphamide vs megestrol acetate in progressive and advanced cancer patients having exhausted all effective therapies under standard care...
  3. pmc Prediction of early death among patients enrolled in phase I trials: development and validation of a new model based on platelet count and albumin
    A Ploquin
    Centre Oscar Lambret, Medical Oncology Department, 3 rue Combemale, Lille 59020, France
    Br J Cancer 107:1025-30. 2012
    ..This study developed an alternative prognostic model, and compared its performance with that of the RMS...
  4. pmc Predictive value of clinical judgment of tumour progression in phase II trials
    Nuria Kotecki
    Centre Oscar Lambret, Lille, France
    PLoS ONE 7:e52638. 2012
    ..The diagnosis of tumour progression or progressive disease (PD) is a key element for designing and interpreting contemporary phase II trials. In some cases, PD is stated by the physician and is not formally confirmed by imaging...
  5. pmc Frequency of certain established risk factors in soft tissue sarcomas in adults: a prospective descriptive study of 658 cases
    Nicolas Penel
    Département de Cancérologie Générale, Centre Oscar Lambret, 59020 Lille, France
    Sarcoma 2008:459386. 2008
    ..Frequency of underlying genetic syndrome which may predispose to soft tissue sarcomas could be higher than previously reported...
  6. pmc Solitary fibrous tumors and so-called hemangiopericytoma
    Nicolas Penel
    General Oncology Department, Centre Oscar Lambret, 3 Rue F Combemale, 59020 Lille, France
    Sarcoma 2012:690251. 2012
    ..We have discussed the emerging concepts on the tumor biology and the different systemic treatments (chemotherapy and molecular-targeted therapies)...
  7. ncbi request reprint Activity endpoints reported in soft tissue sarcoma phase II trials: quality of reported endpoints and correlation with overall survival
    Nicolas Penel
    General Oncology Department, Centre Oscar Lambret, Lille, France Unit Research EA 2694, Medical School, Lille Nord de France University, Lille, France Electronic address
    Crit Rev Oncol Hematol 88:309-17. 2013
    ..Therefore we performed a systematic review of the literature to improve our understanding of the reasons that explain these failures...
  8. pmc Long-term outcome and effect of maintenance therapy in patients with advanced sarcoma treated with trabectedin: an analysis of 181 patients of the French ATU compassionate use program
    Jean Yves Blay
    Centre Leon Berard, Lyon, France
    BMC Cancer 13:64. 2013
    ..The long term outcome of advanced sarcoma patients treated with trabectedin outside of clinical trials and the utility of maintenance treatment has not been reported...
  9. doi request reprint Growth modulation index as metric of clinical benefit assessment among advanced soft tissue sarcoma patients receiving trabectedin as a salvage therapy
    N Penel
    Medical Oncology Department, Centre Oscar Lambret, Lille, France
    Ann Oncol 24:537-42. 2013
    ..The growth modulation index (GMI) is the ratio of time to progression with the nth line (TTP(n)) of therapy to the TTP(n)(-1) with the n-1th line. GMI >1.33 is considered as a sign of activity in phase II trials...
  10. pmc What does a modified-Fibonacci dose-escalation actually correspond to?
    Nicolas Penel
    Methodology and Biostatistics Unit, Centre Oscar Lambret, 3 Rue Frederic Combemale, 59020, Lille Cedex, France
    BMC Med Res Methodol 12:103. 2012
    ..In most phase I oncology trials, it is often stated that the dose increments follow a "modified-Fibonacci sequence". This term, however, is vague...
  11. doi request reprint Cancer-associated hypercalcemia: validation of a bedside prognostic score
    Nicolas Penel
    Département de Cancérologie Générale, Centre Oscar Lambret, 3, rue F Combemale, 5902 Lille, France
    Support Care Cancer 17:1133-5. 2009
    ..Until now, there was no validated and reliable tool to estimate life expectancy among patients with cancer-associated hypercalcemia (CAH). This study aimed to validate a prognostic score previously published...
  12. doi request reprint "Classical 3 + 3 design" versus "accelerated titration designs": analysis of 270 phase 1 trials investigating anti-cancer agents
    Nicolas Penel
    Département de Cancérologie Générale, Centre Oscar Lambret, 3, rue F Combemale, 59020, Lille, France
    Invest New Drugs 27:552-6. 2009
    ..These data support that ATD as an effective clinical trial design over a standard 3 + 3 dose escalation design...
  13. doi request reprint Cyclophosphamide-based metronomic chemotherapy: after 10 years of experience, where do we stand and where are we going?
    Nicolas Penel
    Département de Cancérologie Générale, Centre Oscar Lambret, Lille, France
    Crit Rev Oncol Hematol 82:40-50. 2012
    ..Further clinical trials integrating translational research are necessary to better evaluate the clinical benefit of this promising approach...
  14. doi request reprint Predictors for establishing recommended phase 2 doses: analysis of 320 dose-seeking oncology phase 1 trials
    Nicolas Penel
    Département de Cancérologie Générale, Centre Oscar Lambret, 3 Rue F Combemale, 59020 Lille, France
    Invest New Drugs 30:653-61. 2012
    ..Recent studies suggest that this toxicity-based strategy is not suitable for modern anti-cancer agents. We conducted a retrospective study to identify the risk factor(s) for failing to determine the RP2D according to the MTD...
  15. pmc Adjuvant radiation therapy in metastatic lymph nodes from melanoma
    Jean Emmanuel Bibault
    Academic Radiotherapy Departement, CLCC Oscar Lambret Comprehensive Cancer Center, Lille Nord de France University, Lille, France
    Radiat Oncol 6:12. 2011
    ..To analyze the outcome after adjuvant radiation therapy with standard fractionation regimen in metastatic lymph nodes (LN) from cutaneous melanoma...
  16. doi request reprint Phase II trial of weekly paclitaxel for unresectable angiosarcoma: the ANGIOTAX Study
    Nicolas Penel
    Département de Cancérologie Générale, Centre Oscar Lambret, Lille, France
    J Clin Oncol 26:5269-74. 2008
    ..The objective of this phase II trial was to assess the efficacy and toxicity of weekly paclitaxel for patients with metastatic or unresectable angiosarcoma...
  17. ncbi request reprint Report of eight recent cases of locally advanced primary pulmonary artery sarcomas: failure of Doxorubicin-based chemotherapy
    Nicolas Penel
    Département de Cancérologie Générale, Oscar Lambret Cancer Centre, Lille, France
    J Thorac Oncol 3:907-11. 2008
    ..Case reports of primary pulmonary artery sarcomas are very rare...
  18. doi request reprint Vancomycin flush as antibiotic prophylaxis for early catheter-related infections: a cost-effectiveness analysis
    Nicolas Penel
    Département de Cancérologie Générale, Centre Oscar Lambret, 3 Rue F Combemale, 59020 Lille, France
    Support Care Cancer 17:285-93. 2009
    ..Some recent data suggest that vancomycin flush (VF) administered on the day of catheter insertion could reduce the CRI incidence, but VF could also induce infections by vancomycin-resistant Enterococcus sp. (VRE)...
  19. doi request reprint O-Mel-Inib: a Cancéro-pôle Nord-Ouest multicenter phase II trial of high-dose imatinib mesylate in metastatic uveal melanoma
    Nicolas Penel
    Département de Cancérologie Générale, Centre Oscar Lambret, 59020, Lille, France
    Invest New Drugs 26:561-5. 2008
    ..Nowadays, there is no consensual and effective treatment in metastatic uveal melanoma (MUM). Numerous preclinical data (for example, 75% of MUM express c-kit) suggest that imatinib mesylate (IM) may be a potential treatment of UMM...
  20. ncbi request reprint General practitioners assessment of a structured report on medical decision making by a regional multidisciplinary cancer committee
    Nicolas Penel
    Département de Cancérologie Générale, Centre Oscar Lambret, Lille
    Bull Cancer 94:E23-6. 2007
    ..This SR appears clearly an opportunity of communication amelioration between care providers. This SR is appreciated by GPs. But, it is necessary to include more practical information...
  21. ncbi request reprint Development of a score that predicts survival among patients with bone metastasis revealing solid tumor
    Nicolas Penel
    Département de Cancérologie Générale, Centre Oscar Lambret, 3 Rue F Combemale, Lille, France
    Support Care Cancer 16:1089-93. 2008
    ..Nevertheless, decision making is very difficult because of lack of reliable guidance for life expectancy. Therefore, we had conducted a retrospective study to analyze prognostic factors in this vulnerable population...
  22. ncbi request reprint Factors favouring palliative treatment multidisciplinary decisions for newly diagnosed visceral and soft tissue sarcomas
    N Penel
    Département de Cancérologie Générale, Centre Oscar Lambret, Equipe d Accueil 2694 Santé Publique, Epidémiologie et modélisation des maladies chroniques, université Lille II, Lille, France
    Clin Oncol (R Coll Radiol) 20:523-7. 2008
    ..The aim of this retrospective study was to establish the rationale parameters that justify this decision for newly diagnosed sarcomas...
  23. ncbi request reprint Prognostic factors for adult sarcomas of head and neck
    N Penel
    Département de Cancérologie Générale, Centre Oscar Lambret, Lille, France
    Int J Oral Maxillofac Surg 37:428-32. 2008
    ..005). After taking into account grade and metastasis at presentation, quality of surgery has prognostic value. The primary aim of a multidisciplinary approach to these tumours must favour complete resection...
  24. ncbi request reprint Angiosarcomas and taxanes
    Nicolas Penel
    Département de Cancérologie Générale, Centre Oscar Lambret, 3, rue F Combemale, Lille 59020, France
    Curr Treat Options Oncol 8:428-34. 2007
    ..Further clinical studies are needed to confirm clinic impact of weekly paclitaxel on survival and to assess the role of taxanes in the multidisciplinary treatment of AS...
  25. doi request reprint Development and validation of a model that predicts early death among cancer patients participating in phase I clinical trials investigating cytotoxics
    Nicolas Penel
    Département de Cancérologie Générale, Centre Oscar Lambret, 3, rue F Combemale, Lille, France
    Invest New Drugs 28:76-82. 2010
    ..Given the lack of clear and reliable guidance for the estimation of life expectancy, we retrospectively assessed predictive factors of early death (within 90 days following inclusion) among these patients...
  26. pmc Performance status is the most powerful risk factor for early death among patients with advanced soft tissue sarcoma: the European Organisation for Research and Treatment of Cancer-Soft Tissue and Bone Sarcoma Group (STBSG) and French Sarcoma Group (FSG)
    N Penel
    Department of General Oncology, Centre Oscar Lambret, Regional Comprehensive Cancer Centre, 3, rue F Combemale, 59020, Lille, France
    Br J Cancer 104:1544-50. 2011
    ..We investigated prognostic factors (PFs) for 90-day mortality in a large cohort of advanced/metastatic soft tissue sarcoma (STS) patients treated with first-line chemotherapy...
  27. doi request reprint Testing new regimens in patients with advanced soft tissue sarcoma: analysis of publications from the last 10 years
    N Penel
    European Organisation for Research and Treatment of Cancer Headquarters, EORTC, Brussels, Belgium
    Ann Oncol 22:1266-72. 2011
    ..The prognosis of advanced soft tissue sarcoma remains poor. Many phase II trials investigating new regimens have been published in the last 10 years...
  28. doi request reprint Angiosarcoma: state of the art and perspectives
    Nicolas Penel
    EORTC Headquarters, Belgium
    Crit Rev Oncol Hematol 80:257-63. 2011
    ..Biological evidences for the key role of angiogentic factors have been accumulated during the last years and support the further investigation of anti-angiogenetic agents alone and almost combination with chemotherapy in such disease...
  29. doi request reprint Imatinib for progressive and recurrent aggressive fibromatosis (desmoid tumors): an FNCLCC/French Sarcoma Group phase II trial with a long-term follow-up
    N Penel
    Department of General Cancerology, Oscar Lambret Center, Lille, France
    Ann Oncol 22:452-7. 2011
    ..Imatinib evaluated as a new treatment option in patients with recurrent or established progressive aggressive fibromatosis/desmoid tumor (AF/DT)...
  30. doi request reprint Nature and subjectivity of dose-limiting toxicities in contemporary phase 1 trials: comparison of cytotoxic versus non-cytotoxic drugs
    Nicolas Penel
    Centre Oscar Lambret, 3 Rue Frederic Combemale, 59020, Lille Cedex, France
    Invest New Drugs 29:1414-9. 2011
    ..However, the nature of these DLTs is different from those described with cytotoxic drugs and less objectively measurable in many cases...
  31. doi request reprint Proposal for size justification of expanded cohort at phase-2-recommended dose
    Nicolas Penel
    Département de Cancérologie Générale, Centre Oscar Lambret, Lille, France
    Invest New Drugs 29:713-5. 2011
    ..Nevertheless, the sample size of this expanded cohort has generally not been justified...
  32. ncbi request reprint [Phases 0, 1 and 2 oncology clinical trials: current questions]
    N Penel
    Centre Oscar Lambret, Département de Cancérologie Générale, 3 Rue Frederic Combemale, 59000 Lille, France
    Bull Cancer 97:55-63. 2010
    ..We also discuss the difficulties to apply such methodologies to molecular targeted therapies development...
  33. ncbi request reprint Factors affecting the outcome of patients with metastatic leiomyosarcoma treated with doxorubicin-containing chemotherapy
    N Penel
    General Oncology Department, Centre Oscar Lambret, Lille, France
    Ann Oncol 21:1361-5. 2010
    ..To determine whether pulmonary metastasectomy or the addition of ifosfamide/dacarbazine to a doxorubicin-containing regimen offers a survival benefit to adult patients with metastatic leiomyosarcoma...
  34. doi request reprint Justification of the starting dose as the main determinant of accrual time in dose-seeking oncology phase 1 trials
    Nicolas Penel
    Département de Cancérologie Générale, Centre Oscar Lambret, 3, rue F Combemale, 59020, Lille, France
    Invest New Drugs 28:839-43. 2010
    ..New drug development is a time- and resource-consuming process. Phase 1 trials constitute a major key-step of this development. Shortening the accrual time is of major importance...
  35. pmc Development and validation of a bedside score to predict early death in cancer of unknown primary patients
    Nicolas Penel
    Département de Cancérologie Générale, Centre Oscar Lambret, Lille, France
    PLoS ONE 4:e6483. 2009
    ..We have investigated predictors of 90-day-mortality in a large cohort of non-specific cancer of unknown primary patients...
  36. ncbi request reprint Factors determining length of the postoperative hospital stay after major head and neck cancer surgery
    Nicolas Penel
    Département de Cancérologie Générale, Centre Oscar Lambret, 3 Rue F Combemale, Lille, France
    Oral Oncol 44:555-62. 2008
    ..Two variables (duration of surgical procedure and occurrence of nosocomial infections) were associated with LOS and might be improved by appropriate strategies...
  37. ncbi request reprint Prognostic factors among cancer patients with good performance status screened for phase I trials
    Nicolas Penel
    Département de Cancérologie Générale, Centre Oscar Lambret, Lille 3, rue F Combemale, 59020, Lille, France
    Invest New Drugs 26:53-8. 2008
    ..We retrospectively assessed prognostic factors in cancer patients screened for Phase1 trials between October 1997 and October 2002...
  38. ncbi request reprint [Diagnostic management of inaugurable metastases]
    Nicolas Penel
    Département de Cancérologie Générale, Centre Oscar Lambret 3, rue F Combemale, 59020 Lille Cedex
    Presse Med 32:990-6, 1004. 2003
    ..Positron emission scintigraphy would merit further evaluation...
  39. ncbi request reprint [Prognosis and possibilities of treatment of inaugural metastases]
    Nicolas Penel
    Département de Cancérologie Générale, Centre Oscar Lambret 3, rue F Combemale, 59020 Lille Cedex
    Presse Med 32:997-1004. 2003
    ..Other therapeutic possibilities Excluding these forms, no chemotherapy regimen is a gold standard. Best supportive care is an acceptable option. There is little data on locoregional treatments...
  40. ncbi request reprint [Analysis of the factors influencing the internal reporting of nosocomial infections. A review of 108 notifications]
    N Penel
    Département de Cancérologie Générale, Centre Oscar Lambret, Lille
    Presse Med 32:1797-801. 2003
    ..However, the modalities of internal reporting to the Clin are unknown...
  41. ncbi request reprint [Frequency of genetic diseases and cancer antecedents in 493 adults with visceral or soft tissue sarcomas]
    Nicolas Penel
    Département de Cancérologie Générale, Comité Sarcome du centre Oscar Lambret, 3, rue Frederic Combemale, 59020 Lille
    Bull Cancer 90:887-95. 2003
    ..Those sarcomas are high grade (10 grade III tumours). ASTS epidemiology is complex with different risk factors depending on histologic type...
  42. ncbi request reprint Causes of fever and value of C-reactive protein and procalcitonin in differentiating infections from paraneoplastic fever
    Nicolas Penel
    Département de Cancérologie Générale, Centre Oscar Lambret, 3 Rue F Combemale, 59020 Lille, France
    Support Care Cancer 12:593-8. 2004
    ..The aims of our retrospective study were to study first the causes of 245 febrile episodes in cancer patients and then the value of procalcitonin (PCT) and C-reactive protein (CRP) in differentiating infections from paraneoplastic fever...
  43. ncbi request reprint Previous chemotherapy as a predictor of wound infections in nonmajor head and neck surgery: Results of a prospective study
    Nicolas Penel
    Hygiene Unit, Centre Oscar Lambret, Lille, France
    Head Neck 26:513-7. 2004
    ..The goal of this prospective study was to determine the incidence of wound infections (WI) after clean uncontaminated head and neck cancer procedures and after emergency tracheotomies...
  44. ncbi request reprint Multivariate analysis of risk factors for wound infection in head and neck squamous cell carcinoma surgery with opening of mucosa. Study of 260 surgical procedures
    Nicolas Penel
    General Oncology Department, Centre Oscar Lambret, 3, rue F Combemale 59020 Lille, France Hygiene Unit, Centre Oscar Lambret, Lille, France
    Oral Oncol 41:294-303. 2005
    ..This study identified one major risk factor, post-laryngectomy tracheostomy. Long-term curative antibiotherapy must be evaluated in cancer head and neck surgery requiring post-laryngectomy tracheostoma...
  45. ncbi request reprint Prognostic significance of wound infections following major head and neck cancer surgery: an open non-comparative prospective study
    Nicolas Penel
    Comité de Lutte contre les Infections Nosocomiales, Centre Oscar Lambret, Lille, France
    Support Care Cancer 12:634-9. 2004
    ..We evaluated the incidence, risk factors and consequences of wound infection (WI) following major head and neck cancer surgery in an open non-comparative study...
  46. ncbi request reprint Head and neck soft tissue sarcomas of adult: prognostic value of surgery in multimodal therapeutic approach
    Nicolas Penel
    General Oncology Department, Centre Oscar Lambret, 3, rue F Combemale 59020, Lille, France
    Oral Oncol 40:890-7. 2004
    ..Rhabdomyosarcomas (p = 0.005) and inadequate resection (p = 0.04) were associated with poor outcome. Large resection of AHNSTS in a multimodality approach may afford the best chance of disease control...
  47. ncbi request reprint [Primary soft tissue sarcoma of the chest in adults: a retrospective study of 40 cases]
    N Penel
    Département de Cancérologie Générale, Centre Oscar Lambret, 3, rue F Combemale, 59020, Lille, France
    Ann Chir 128:237-45. 2003
    ..The aim of the study was to report a series of 40 patients with PTSTS, with analysis of their clinico-pathological characteristics, management, and prognostic factors...
  48. ncbi request reprint Primary mucosal melanoma of head and neck: prognostic value of clear margins
    Nicolas Penel
    General Oncology Department, Oscar Lambret Cancer Center, Lille, France
    Laryngoscope 116:993-5. 2006
    ..Primary mucosal melanomas of the head and neck (MMHN) are rare and carry a poor outcome. The impact of different treatments on survival is not yet clearly established...
  49. ncbi request reprint Cancer-associated hypercalcemia treated with intravenous diphosphonates: a survival and prognostic factor analysis
    Nicolas Penel
    Département de Cancérologie Générale, Centre Oscar Lambret, Lille, France
    Support Care Cancer 16:387-92. 2008
    ..Cancer-associated hypercalcemia (CAH) is the most frequent metabolic disorder in cancer patients. We retrospectively reviewed the outcome and prognostic factors for patients with CAH being treated with standard intravenous disphosphonates...
  50. ncbi request reprint Prognosis of hypercalcemia in aerodigestive tract cancers: study of 136 recent cases
    Nicolas Penel
    Département de Cancérologie Générale, Centre Oscar Lambret, 3, rue F Combemale, 59020 Lille, France
    Oral Oncol 41:884-9. 2005
    ..16 CI 95% 1.01-4.63). Despite use of diphosphonates (infusions of pamidronate), hypercalcemia is associated with very poor prognosis. Tumour location and level of calcemia had no prognostic value...
  51. ncbi request reprint Risk factors for early catheter-related infections in cancer patients
    Nicolas Penel
    Department of General Oncology, Oscar Lambret Cancer Center, Lille, France
    Cancer 110:1586-92. 2007
    ..The authors conducted a prospective study to identify the risk factors for developing early catheter-related infection...
  52. ncbi request reprint Prevention of surgical site infection after breast cancer surgery by targeted prophylaxis antibiotic in patients at high risk of surgical site infection
    Nicolas Penel
    Département de Cancérologie Générale, Centre Oscar Lambret, France
    J Surg Oncol 96:124-9. 2007
    ..The present before-after study evaluated a preventive strategy for high-risk patients...
  53. ncbi request reprint [Anticancer chemotherapy, risk factor for infection at the operated site in cervicofacial surgery]
    N Penel
    Département de Cancérologie Cervico Faciale, Centre Oscar Lambret, 3, rue F Combemale, BP 307, F 59020 Lille
    Presse Med 30:892-5. 2001
    ..In order to evaluate occurrence and risk factors for wound infection (WI) in head and neck uncontaminated surgery, we carried out a prospective study...
  54. ncbi request reprint [Epidemiology of soft tissue sarcomas in adults]
    N Penel
    Département de Cancérologie Générale, CHRU de Lille, CERESTE, Universite de Lille II
    Presse Med 30:1405-13. 2001
    ..FURTHER RESEARCH: Little is known about the epidemiology of soft tissue sarcoma. Case-control studies are needed...
  55. ncbi request reprint A simple predictive model for postoperative mortality after head and neck cancer surgery with opening of mucosa
    Nicolas Penel
    General Oncology Department, Oscar Lambret Centre, 3 Rue F Combemale, Lille 59020 BP 207, France
    Oral Oncol 43:174-80. 2007
    ..63% for patients without risk factor and was 6.41% for those with one or two risk factors. This model identifies easily high-risk patients for major head and neck cancer surgery. A multicenter validation is necessary...
  56. ncbi request reprint [A prospective evaluation of antibiotic prophylaxis efficacy for breast cancer surgery following previous chemotherapy]
    Nicolas Penel
    Département de Cancérologie Générale, Centre Oscar Lambret, 3, rue F Combemale, 59020 Lille
    Bull Cancer 91:445-8. 2004
    ..0). This study suggests that AP is not systematically required in breast cancer surgery following previous anticancer chemotherapy...
  57. pmc A dose-escalating phase I of imatinib mesylate with fixed dose of metronomic cyclophosphamide in targeted solid tumours
    A Adenis
    1 Department of Medical Oncology, Centre Oscar Lambret, 3, rue F Combemale, Lille, France 2 Catholic University of Lille, Medical School, Lille, France
    Br J Cancer 109:2574-8. 2013
    ..Preclinical findings suggest that imatinib mesylate (IM) and metronomic cyclophosphamide (MC) combination provides synergistic antiangiogenic activity on both pericytes and endothelial cells...
  58. ncbi request reprint Risk factors for wound infection in head and neck cancer surgery: a prospective study
    N Penel
    Head and Neck Cancer Department, Oscar Lambret Cancer Center, 3 rue F. Combemale, Lille 59020 BP 207, France
    Head Neck 23:447-55. 2001
    ..008). CONCLUSIONS: Despite antibiotic prophylaxis, WI occurrence is high. These data inform the head and neck surgeon, when a patient is at risk for WI and may help to design future prospective studies...
  59. ncbi request reprint [Incidence and surgical wound infection risk factors in breast cancer surgery]
    D Lefebvre
    Comité de Lutte contre les Infections Nosocomiales, Centre Oscar Lambret, Lille
    Presse Med 29:1927-32. 2000
    ..In order to evaluate occurrence and risk factors for wound infection (WI) in breast cancer surgery, we carried out a prospective study...
  60. ncbi request reprint Correlation between overall survival and growth modulation index in pre-treated sarcoma patients: a study from the French Sarcoma Group
    S Cousin
    Department of General Oncology, Oscar Lambret Center, Lille
    Ann Oncol 24:2681-5. 2013
    ..Nevertheless, its use has been limited until now...
  61. ncbi request reprint Metastatic angiosarcomas: doxorubicin-based regimens, weekly paclitaxel and metastasectomy significantly improve the outcome
    N Penel
    Sarcoma Unit, Department of General Oncology, Centre Oscar Lambret, Lille, France
    Ann Oncol 23:517-23. 2012
    ..Angiosarcomas are a rare but aggressive form of soft tissue sarcoma. At metastatic stage, the clinical benefit of therapeutic intervention remains debatable...
  62. ncbi request reprint [Fever and solid tumor: diagnostic value of procalcitonin and C-reactive protein]
    N Penel
    Département de cancérologie cervicofaciale, Centre Oscar Lambret, 3, rue F Combemale, 59020 Lille, France
    Rev Med Interne 22:706-14. 2001
    ..Evaluate the clinical utility of procalcitonin (PCT) and C-reactive protein (CRP) as diagnostic of paraneoplastic fever...
  63. doi request reprint Cancer-associated hypercalcaemia in squamous-cell malignancies: a survival and prognostic factor analysis
    F Le Tinier
    Medical Oncology Department, Centre Oscar Lambret, Lille, France
    Int J Oral Maxillofac Surg 40:938-42. 2011
    ..The bedside prognostic score that the authors developed can help to anticipate patients' prognosis and adapt the treatment. This score needs to be validated on an independent cohort...
  64. ncbi request reprint [Soft sarcoma tissue of extremities: medical imagery in post-therapeutic follow-up]
    S Taieb
    Departement d Imagerie, Centre Régional de Lutte Contre le Cancer Oscar Lambret, 3, rue Frederic Combemale, BP 309, 59020 Lille Cedex, France
    Cancer Radiother 10:78-82. 2006
    ....
  65. doi request reprint Individual life expectancy estimation using validated prognostic scores for patients with cancer of unknown primary
    Charles Ferte
    Département de Cancérologie Générale, Centre de lutte contre le cancer Oscar Lambret, Lille, France
    Oncology 78:87-93. 2010
    ..To implement 3 published prognostic scores in an independent set of patients with cancer of unknown primary (CUP), and compare their performance on individual life expectancy prediction...
  66. doi request reprint Totally implantable venous access port systems and risk factors for complications: a one-year prospective study in a cancer centre
    F Narducci
    Centre Régional de Lutte Contre le Cancer Oscar Lambret, 3 Rue Frederic Combemale, BP 307, 59020 Lille Cedex, France
    Eur J Surg Oncol 37:913-8. 2011
    ..The aim of this study was to investigate possible risk factors for morbidity...
  67. ncbi request reprint [Definitions of target volumes in soft tissue sarcomas of the extremities]
    E Lartigau
    Departement de Radiotherapie, Centre Oscar Lambret, rue F Combemale, 59000 Lille, France
    Cancer Radiother 5:695-703. 2001
    ..General rules for this irradiation (doses, volumes) and principal results will be presented...
  68. ncbi request reprint [Prognosis of post-irradiation soft-tissue sarcoma: case-control study]
    C Leclercq
    Département de Cancérologie Générale, Centre Oscar Lambret, 3, rue Frederic Combemale, BP 307, 59020, Lille Cedex, France
    Rev Med Interne 25:866-71. 2004
    ..We describe clinical and pathological aspects and survival of 12 recent of radio-induced soft tissue sarcoma...
  69. ncbi request reprint [Ultra-late metastasis of ocular melanoma: about two cases]
    J Grosjean
    Département de Cancérologie Générale, Centre Oscar Lambret, Lille, France
    Rev Med Interne 25:147-9. 2004
    ..Ocular melanoma is associated with extended risk of metastases, mainly liver metastases. Nevertheless, the late and ultra-late recurrence (respectively 10 and 15 years after initial treatment) are exceptional events...
  70. ncbi request reprint [Soft tissue sarcoma: role of imaging for initial diagnosis and treatment]
    S Taieb
    Departement d Imagerie, Centre Régional de Lutte Contre le Cancer Oscar Lambret, 3, rue Frederic Combemale, BP 309 59020 Lille cedex, France
    Cancer Radiother 10:22-33. 2006
    ..The role of PET begins to be more clear in case of need global assessment before radical surgery. A multidisciplinary approach is essential to perform rational treatment planning and avoid partial surgery...
  71. ncbi request reprint [Primary leiomyosarcoma of pulmonary artery: a rare tumor mis-diagnosed as pulmonary embolism]
    V Lecoeuvre
    Département de Cancérologie Générale, Centre Oscar Lambret, Lille, France
    Rev Med Interne 24:45-8. 2003
    ..Primary leiomyosarcoma of the pulmonary artery is an extremely rare tumor that is frequently misdiagnosed as chronic pulmonary embolism...
  72. ncbi request reprint [Treatment of adult patients with metastatic sarcoma: current shift in concepts]
    N Penel
    Centre Oscar Lambret, Département de Cancérologie Générale, 3, rue F Combemale, 59020 Lille, France
    Bull Cancer 97:687-91. 2010
    ....
  73. ncbi request reprint [Induction chemotherapy and larynx preservation: is such practice useful?]
    Jérôme Sarini
    Département de Cancérologie Cervico Faciale, Centre Oscar Lambret, 3, rue Frederic Combemale, 59020 Lille Cedex
    Bull Cancer 89:411-7. 2002
    ..Are results obtained in daily induction chemotherapy usefulness identical to results obtained in larynx preservation studies?..
  74. doi request reprint [Prognostic and predictive factors of soft tissue sarcoma: a daily use of translational research]
    C Ferte
    Département de Cancérologie Générale, Centre Oscar Lambret, 59020 Lille, France
    Bull Cancer 96:451-60. 2009
    ..Soft-tissue sarcoma is a heterogeneous group of diseases. Prognostic factors for local recurrence, metastatic recurrence, and overall survival are different and optimal treatment strategies need to take them into account...
  75. ncbi request reprint Pronostic factors of synchronous brain metastases from lung cancer
    N Penel
    Oscar Lambret Cancer Center, rue Frederic Combemale, B.P. 307, 59020 Lille, France
    Lung Cancer 33:143-54. 2001
    ..However, further studies are necessary to evaluate quality of life with or without carcinologic treatment...
  76. ncbi request reprint The free vascularized flap and the pectoralis major pedicled flap options: comparative results of reconstruction of the tongue
    Y Mallet
    Centre Oscar Lambret, BP 307, 59020 Lille Cedex, France
    Oral Oncol 45:1028-31. 2009
    ..The assessment of our practice in the case of extensive tongue defect suggests that reconstruction with free soft-tissue transfer, whenever feasible, should be the first-choice treatment option...
  77. doi request reprint Imaging of the most frequent superficial soft-tissue sarcomas
    Melanie Morel
    Department of Radiology, Centre Oscar Lambret, 03, rue Frederic Combemale, BP 307, 59020, Lille, France
    Skeletal Radiol 40:271-84. 2011
    ....
  78. ncbi request reprint Soft tissue sarcomas or intramuscular haematomas?
    Sophie Taieb
    Department of Radiology, Centre Oscar Lambret, 03, rue Frederic Combemale, BP 307, 59020 Lille Cedex, France
    Eur J Radiol 72:44-9. 2009
    ..The diagnosis of a high grade sarcoma must be considered in these patients and any doubt should be resolved with a biopsy to avoid tragic consequences of missed sarcoma...
  79. ncbi request reprint Vinorelbine in breast cancer
    Jacques Bonneterre
    Centre Oscar Lambret, Breast Cancer Department, 3 Rue Frederic Combemale, 59020 Lille Cedex, France
    Expert Opin Pharmacother 9:2901-10. 2008
    ..A synergistic effect has been observed between vinorelbine and trastuzumab in patients with a hyperexpression of HER2 in their tumours...
  80. ncbi request reprint When cancerophobia and denial lead to death
    Michel Reich
    Psycho Oncology Team, Centre Oscar Lambret, Lille, France
    Palliat Support Care 7:253-5. 2009
    ..When it turns out to be ineffective and pathological, it can cause either delay or avoidance in seeking treatment for symptoms relevant for a true malignancy and will lead inexorably to death if not cured...
  81. ncbi request reprint [Interest of imaging for the monitoring of a treated cancer: simplified use of likelyhood ratio. The example of soft tissue tumor]
    Sophie Taieb
    Departement d Imagerie, Centre Regional de Lutte Contre le Cancer, Oscar Lambret, 3, rue Frédéric, Combemale, BP 309 59020, Lille Cedex
    Bull Cancer 93:1201-6. 2006
    ..The Bayes'nomogram is useful to assess diagnosis test. Soft tissue sarcoma is a example of such demonstration...
  82. ncbi request reprint Survival prognostic factors for lateral bucco-pharyngeal junction squamous cell carcinoma
    Yann Mallet
    Head and Neck Cancerology Department, Centre Oscar Lambret, Lille, France
    Eur Arch Otorhinolaryngol 265:S25-8. 2008
    ..For example, surgery must be proposed whenever deemed possible. It is in an independent factor in our series. All the statuses linked to the population type, tumor extension and tumor differentiation are also discussed...
  83. ncbi request reprint [Cancers and pesticides: current data]
    Nicolas Penel
    Département de Cancérologie Générale, Centre Oscar Lambret, 3, rue Frederic Combemale, 59020, Lille
    Bull Cancer 94:15-22. 2007
    ..But, most of epidemiological studies are not conclusive but of the difficulty to measure the exposure to pesticides. The future epidemiological studies may include toxicological analysis in order to measure the exposure...
  84. doi request reprint Imatinib in gastrointestinal stromal tumor: does treatment duration matter?
    Antoine Adenis
    Department of Medical Oncology, Centre Oscar Lambret, Lille, France
    Oncology 77:157-61. 2009
    ..This review provides a clinical perspective on the available data, evidence- or expert-based, for calculating the optimal treatment duration with imatinib...
  85. doi request reprint Palliative chemotherapy does not improve survival in metastatic esophageal cancer
    Antoine Adenis
    Faculté Libre de Médecine, Department of Gastrointestinal and Urological Oncology, Catholic University, Lille, France
    Oncology 79:46-54. 2010
    ..The role of chemotherapy in metastatic esophageal carcinoma (MEC) remains a matter of debate. The aim of this retrospective study was to analyze the survival impact of chemotherapy after stratification for prognostic factors...
  86. ncbi request reprint Oral metronomic cyclophosphamide in elderly with metastatic melanoma
    Estelle Borne
    Clinique de Dermatologie, Centre Hospitalier Regional et Universitaire, Universite Lille 2, Lille, France
    Invest New Drugs 28:684-9. 2010
    ..Conventional chemotherapy frequently induces imbalance in frail physiological cases. We propose to treat these patients with oral metronomic cyclophosphamide...
  87. ncbi request reprint [Clinical equipoise and randomised clinical trials in oncology]
    C Ferte
    Département de Cancérologie Générale, Centre Oscar Lambret, Lille, France
    Bull Cancer 96:727-31. 2009
    ..We had defined, discussed and illustrated the principle of clinical equipoise that ethically and methodologically justifies the randomisation in clinical trials...
  88. ncbi request reprint [Methodological approaches of clinical studies with targeted therapies]
    Nicolas Penel
    Département de Cancérologie Générale, Centre Oscar Lambret, 3, rue F Combemale, 59020 Lille, France
    Bull Cancer 95:185-90. 2008
    ..The discontinuation treatment studies and the validation of biomarkers (as surrogate endpoints or as classifiers) are the two main particularities of phase III studies designed for the assessment of molecular targeted therapies...
  89. ncbi request reprint [An index of understanding randomised clinical trials in oncology]
    Tanguy Leroy
    Univ Lille Nord de France Université de Lille III URECA EA 1059, BP 60149 F 59653 Villeneuve d Ascq Cedex, Centre Oscar Lambret, Lille, France
    Bull Cancer 96:741-50. 2009
    ..Better evaluations of the knowledge of the patients who participate to randomised clinical trials seem to be a distinct asset to improve these patients' global clinical care...
  90. ncbi request reprint [Gene therapy of melanoma: review of published clinical trials]
    N Penel
    Département de Cancérologie Générale, Centre Oscar Lambret, 3, rue F Combemale, 59020 cedex, Lille, France
    Rev Med Interne 24:443-51. 2003
    ..These studies are heterogenous as far as methodology is concerned. Gene therapy clinical tolerance is acceptable. Security is rarely discuted. In these studies overall response rate is 8%, with histological complete responses...
  91. ncbi request reprint Feasibility of sentinel lymph node biopsy in multiple unilateral synchronous breast cancer: results of a French prospective multi-institutional study (IGASSU 0502)
    S Giard
    Department of Surgery and Oncology, Centre Oscar Lambret, Lille, France
    Ann Oncol 21:1630-5. 2010
    ..To prospectively determine the feasibility of sentinel lymph node biopsy (SLNB) in preoperatively diagnosed multiple unilateral synchronous invasive breast cancers...
  92. doi request reprint Publication biases and phase II trials investigating anticancer targeted therapies
    Nicolas Penel
    Medical Oncology, Centre Oscar Lambret, 3 rue Combemale, 59020, Lille, France
    Invest New Drugs 27:287-8. 2009
    ..As a result, we found that the final result of the trial itself was the most important parameter that was related to IF, as the median-IF was significantly lower for negative trials than for positive trials (2.71 vs 6.14, p = 0.004)...
  93. ncbi request reprint Psychosocial factors involved in delayed consultation by patients with head and neck cancer
    Olivier Rozniatowski
    Psycho Oncology Unit, Centre Oscar Lambret, BP 307, 59020 Lille Cedex, France
    Head Neck 27:274-80. 2005
    ..We studied this delay in seeking consultation, focusing on psychosocial variables such as professional and social background, the involvement of a spouse/partner, and the presence of anxiety and depression...
  94. doi request reprint Phase II trials in patients with carcinoma of unknown primary: a pooled data analysis
    Antoine Adenis
    Département de Cancérologie Digestive et Urologique, Centre Oscar Lambret, Lille, France
    Invest New Drugs 28:178-84. 2010
    ..The management of carcinoma of unknown primary site remains debatable. The literature data consists of about 29 phase-II studies investigating 38 regimens, providing a broad range of response rates (RR)...
  95. ncbi request reprint Docetaxel and gemcitabine combination in 133 advanced soft-tissue sarcomas: a retrospective analysis
    Jacques Olivier Bay
    Centre Jean Perrin, Clermont Ferrand, France
    Int J Cancer 119:706-11. 2006
    ..For the other histological subtypes, the response was not encouraging, but the survival for patients in response or stable suggests further investigation...
  96. doi request reprint Primitive neuroectodermal tumour of the duodenum with unexpected lymph node involvement
    Fabienne Watelle
    Scand J Gastroenterol 43:511-2. 2008
  97. doi request reprint [Merkel cell carcinoma: current diagnosis and treatment]
    Laurent Mortier
    Service universitaire de dermatologie, CHU de Lille, France
    Bull Cancer 95:823-7. 2008
    ..We propose herein a review based on literature data about current treatment of Merkel cell carcinoma, including new data on adjuvant radiotherapy and sentinel lymph node biopsy...